var data={"title":"Dapsone (systemic): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dapsone (systemic): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388150?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dapsone-systemic-drug-information\" class=\"drug drug_general\">see &quot;Dapsone (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=dapsone-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dapsone (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10483704\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Sulfone</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Leprostatic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24552552\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Linear IgA bullous dermatosis (LABD):</b> Very limited data available: Term infants: Oral: 0.5 or 1 mg/kg/day; dosing based on experience from two case reports (PNA: 9 days and 20 days) which showed a positive response to dapsone therapy; however, adverse effects hindered treatment course. In the case report involving the youngest patient (PNA: 9 days), the initial dose was 1 mg/kg/day with concurrent prednisolone; the dose was increased to 2 mg/kg/day at which point the neonate developed methemoglobinemia by day 14 of treatment and dapsone was temporarily discontinued; a second course was initiated at 9 months of age for another disease flare at 0.5 mg/kg/day (Gluth, 2004). In the other case report (PNA: 20 days), initial therapy was 0.5 mg/kg/day; the dose was later increased to 1 mg/kg/day; while LABD improved on dapsone therapy, the patient developed pneumonia (highly resistant) which required discontinuation of dapsone (Kishida, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10483725\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dapsone-systemic-drug-information\" class=\"drug drug_general\">see &quot;Dapsone (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatitis herpetiformis:</b> Infants, Children, and Adolescents: Oral: 0.5 to 2 mg/kg/day in 1 to 2 divided doses; maximum initial daily dose in adults: 50 mg/<b>day</b>; once lesions controlled, the dose may be decreased as tolerated for chronic therapy; usual range: 0.125 to 0.5 mg/kg/day (Ermacora, 1986; Kliegman, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Idiopathic thrombocytopenic purpura (ITP), refractory:</b> Limited data available: Children &ge;3 years and Adolescents: Oral: 1 to 2 mg/kg/day for at least 2 months. Dosing based on two retrospective reviews. The first was a retrospective cohort analysis of adult and pediatric (age range: 3-61 years, including 35 patients &lt;16 years) with chronic ITP (&gt;6 months with diagnosis) who failed steroid therapy and observed an overall similar response rate for children (65.7%) and adults (Damodar, 2005). Adverse effects occurred in three patients (one with acute hemolysis and two with an erythematous rash). The second was a small retrospective report of seven pediatric patients with acute or chronic refractory, symptomatic ITP (age range: 6-15 years) which also showed a similar response rate (60%); however, a higher incidence [two of seven patients (29%)] of methemoglobinemia was observed (Meeker, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leprosy:</b> Infants, Children, and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Multibacillary leprosy (6 patches or more): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based: 1 mg/kg/dose once daily; continue for 24 months in combination with other leprosy agents; maximum single dose: 100 mg (<i>Red Book</i> [AAP], 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed-dose (WHO, 2010): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &lt;10 years: 25 mg once daily; continue treatment for 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 10-12 years: 50 mg once daily; continue treatment for 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Paucibacillary leprosy (1-5 patches): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based: 1 to 2 mg/kg/dose once daily; continue for 12 months in combination with other leprosy agents; maximum single dose: 100 mg (<i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Fixed-dose (WHO, 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &lt;10 years: 25 mg once daily; continue treatment for 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 10-12 years: 50 mg once daily; continue treatment for 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Linear IgA bullous dermatosis (LABD):</b> Limited data available: Infants, Children, and Adolescents: Oral: 0.5 to 2 mg/kg/day in 1 to 2 divided doses with or without prednisone; maximum initial daily dose in adults for other indications: 50 to 100 mg/day; may increase if needed at weekly intervals; maximum reported daily dose: 4 mg/kg/<b>day</b> (Kenani, 2009; Kliegman, 2011; Thappa, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Pneumocystis jirovecii</i> pneumonia (PCP):</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis (primary or secondary): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (independent of HIV status including HSCT recipient): 2 mg/kg/dose once daily (maximum single dose: 100 mg) <b>or</b> 4 mg/kg/dose once <b>weekly</b>; maximum single weekly dose: 200 mg) (CDC/IDSA [Tomblyn], 2009; DHHS [pediatric], 2013; <i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents (HIV-exposed/-positive or HSCT recipient): 100 mg/day in 1 or 2 divided doses as monotherapy <b>or</b> 50 mg once daily in combination with weekly pyrimethamine and leucovorin <b>or</b> 200 mg once <b>weekly</b> in combination with weekly pyrimethamine and leucovorin; monotherapy should not be used in patients who are seropositive for <i>Toxoplasma gondii</i> (CDC/IDSA [Tomblyn], 2009; DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment, mild to moderate disease: Infants, Children, and Adolescents (independent of HIV status): 2 mg/kg/dose once daily in combination with trimethoprim for 21 days; maximum single dose: 100 mg (DHHS [adult], 2013; <i>Red Book</i> [AAP], 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Toxoplasma gondii</i>, primary prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children (independent of HIV status): 2 mg/kg/dose <b>or</b> 15 mg/m<sup>2</sup>/dose once daily in combination with pyrimethamine and leucovorin; maximum single dose: 25 mg; a weekly regimen typically used for PCP prophylaxis but which also covers toxoplasma is 4 mg/kg/dose once <b>weekly</b> in combination with weekly pyrimethamine and leucovorin; maximum single weekly dose: 200 mg (DHHS [pediatric], 2013; <i>Red Book</i> [AAP], 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents (HIV-exposed/-positive): 50 mg once daily in combination with weekly pyrimethamine and leucovorin or 200 mg once <b>weekly</b> in combination with weekly pyrimethamine and leucovorin (DHHS [adult], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatitis herpetiformis:</b> Oral: Initial: 50 mg once daily; increase to 300 mg daily or higher to achieve full control; reduce dosage to minimal level as soon as possible </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leprosy:</b> Oral: 100 mg once daily in combination with other antileprosy drugs; duration of therapy is variable </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, some clinicians have used the following: Infants, Children, and Adolescents: No adjustment necessary (Aronoff, 2007).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015379\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9490508\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10483764\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May administer with meals if GI upset occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015308\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 76&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10483705\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of leprosy due to susceptible strains [FDA approved in pediatric patients (age not specified) and adults]; treatment of dermatitis herpetiformis [FDA approved in pediatric patients (age not specified) and adults]; has also been used for prophylaxis and treatment of <i>Pneumocystis jirovecii</i> pneumonia (PCP); prophylaxis against toxoplasmic encephalitis; treatment of linear IgA bullous dermatosis (LABD) and refractory idiopathic thrombocytopenia purpura (ITP)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015264\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dapsone may be confused with Diprosone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015299\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Fever, headache, insomnia, psychosis (oral/topical), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Bullous and exfoliative dermatitis, erythema nodosum, exfoliative dermatitis, morbilliform and scarlatiniform reactions, phototoxicity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypoalbuminemia (without proteinuria), male infertility</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic:  Agranulocytosis, anemia, leukopenia,  pure red cell aplasia (case report); hemolysis (dose related; seen in patients with and without G6PD deficiency), hemoglobin decrease (1-2 g/dL), reticulocyte increase, methemoglobinemia, red cell life span shortened</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Lower motor neuron toxicity (prolonged therapy), lupus-like syndrome, peripheral neuropathy (rare, nonleprosy patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocular:  Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Albuminuria, nephrotic syndrome, renal papillary necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Interstitial pneumonitis, pulmonary eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Infectious mononucleosis-like syndrome (rash, fever, lymphadenopathy, hepatic dysfunction)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015294\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dapsone or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015295\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Aplastic anemia, agranulocytosis and other severe blood dyscrasias (some fatal) have been reported; monitor for signs/symptoms (eg, fever, sore throat, pallor, purpura, jaundice). Closely monitor CBC and discontinue therapy if a significant reduction in leukocytes, platelets, or hemopoiesis is seen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic reactions: Serious dermatologic reactions, including toxic erythema, erythema multiforme, toxic epidermal necrolysis, morbilliform and scarlatiniform reactions, urticaria, and erythema nodosum have been reported rarely. Discontinue therapy if new or severe dermatologic reactions occur; leprosy reactional states (eg, erythema nodosum leprosum) do not require discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Toxic hepatitis and cholestatic jaundice have been reported; hyperbilirubinemia may occur more frequently in G6PD deficient patients. Monitor liver function; discontinue use if abnormalities occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral neuropathy: Motor loss and muscle weakness have been reported; discontinue use if symptoms of peripheral neuropathy develop. Recovery after discontinuation is usually complete; some patients may tolerate retreatment at reduced doses. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfonamide allergy: Use with caution in patients with hypersensitivity to other sulfonamides; sulfone reactions may also occur as potentially fatal hypersensitivity reactions, requiring drug discontinuation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: Use with caution in patients with severe anemia; treat prior to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; G6PD deficiency: Use with caution in patients with G6PD deficiency; dose-related hemolysis and methemoglobinemia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemoglobin M deficiency: Use with caution in patients with hemoglobin M deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobin reductase deficiency: Use with caution in patients with methemoglobin reductase deficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015301\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (major), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015302\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15963&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antimalarial Agents: May enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions. Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Dapsone (Systemic) may enhance the adverse/toxic effect of Atazanavir. Specifically, the risk of hyperbilirubinemia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C9 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP2C9 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP2C9 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifabutin: May decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of Dapsone (Systemic). Dapsone (Systemic) may increase the serum concentration of Trimethoprim.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015289\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015290\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Dapsone crosses the placenta (Brabin 2004). Per the manufacturer, dapsone has not shown an increased risk of congenital anomalies when given during all trimesters of pregnancy. Several reports have described adverse effects in the newborn after in utero exposure to dapsone, including neonatal hemolytic disease, methemoglobinemia, and hyperbilirubinemia (Hocking 1968; Kabra 1998; Thornton 1989). Dapsone may be used in pregnant women requiring maintenance therapy of either leprosy or dermatitis herpetiformis. Dapsone may be used as an alternative agent for management of <i>Pneumocystis jirovecii</i> pneumonia (PCP) or <i>Toxoplasma gondii</i> encephalitis in pregnant, HIV-infected patients (HHS [OI Adult] 2016). Because of the theoretical increased risk for hyperbilirubinemia and kernicterus, neonatal care providers should be informed if maternal dapsone is used near term (HHS [OI Adult] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10483765\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (weekly for the first month, monthly for 6 months, then semiannually), reticulocyte count, and liver function tests; check G-6-PD levels prior to initiation of dapsone; monitor for signs of jaundice, hemolysis, or methemoglobinemia. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015309\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive antagonist of para-aminobenzoic acid (PABA) and prevents normal bacterial utilization of PABA for the synthesis of folic acid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015311\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and almost complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Dapsone: 70% to 90%; Metabolite: ~99% (Zuidema 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.5 L/kg (Zuidema 1986) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (acetylation and hydroxylation); forms multiple metabolites (Zuidema 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children: 15.1 hours (Mirochnick 1993); Adults: 28 hours (range: 10 to 50 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: 4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~85% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015382\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;margin-top:2em;display:inline\">A 2 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;. Crush eight 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &quot;shake well&quot;. Stable for 90 days at room temperature or refrigerated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Jacobus Pharmaceutical Company makes a 2 mg/mL proprietary liquid formulation available under an IND for the prophylaxis of <i>Pneumocystis jirovecii</i> pneumonia.</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, and Trowbridge JM, &quot;Stability of Dapsone in Two Oral Liquid Dosage Forms,&quot; <i>Ann Pharmacother</i>, 2000, 34(7-8):848-50.<span class=\"pubmed-id\">10928393</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322077\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Dapsone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $73.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $90.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390227\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Daps (AR);</li>\n      <li>Dapsomed (BD);</li>\n      <li>Dapson (DK, EG, KR, NL, NO);</li>\n      <li>Dapson-Fatol (DE);</li>\n      <li>Dapsona (CO, CU);</li>\n      <li>Dapsone (AU);</li>\n      <li>Disulone (FR);</li>\n      <li>Dopsan (TH);</li>\n      <li>Lennon-Dapsone (ZA);</li>\n      <li>Lepsone (BD);</li>\n      <li>Pyrisone (SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barnett ED, Pelton SI, Mirochnick M, et al, &quot;Dapsone for Prevention of <i>Pneumocystis</i> Pneumonia in Children With Acquired Immunodeficiency Syndrome&quot; <i>Pediatr Infect Dis J</i>, 1994, 13(1):72-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8170736/pubmed\" target=\"_blank\" id=\"8170736\">8170736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brabin BJ, Eggelte TA, Parise M, Verhoeff F. Dapsone therapy for malaria during pregnancy: maternal and fetal outcomes. <i>Drug Saf</i>. 2004;27(9):633-648.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15230645/pubmed\" target=\"_blank\" id=\"15230645\">15230645</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Damodar S, Viswabandya A, George B, Mathews V, Chandy M, Srivastava A. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults &ndash; a report on 90 patients. <i>Eur J Haematol</i>. 2005;75:328-331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/16146539/pubmed\" target=\"_blank\" id=\"16146539\">16146539</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations From the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a>. Published November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ermacora E, Prampolini L, Tribbia G, et.al. Long-term follow-up of dermatitis herpetiformis in children. <i>J Am Acad Dermatol</i>. 1986;15:24-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/3722506/pubmed\" target=\"_blank\" id=\"3722506\">3722506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gluth MB, Witman PM, Thompson DM. Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis.<i> Int J Pediatr Otorhinolaryngol</i>. 2004;68(7):965-970.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/15183590/pubmed\" target=\"_blank\" id=\"15183590\">15183590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hocking DR, &quot;Neonatal Haemolytic Disease Due to Dapsone,&quot;<i> Med J Aust</i>, 1968,  1(26):1130-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/4969972/pubmed\" target=\"_blank\" id=\"4969972\">4969972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Human Resources and Services Administration, U.S. Department of Health and Human Services. National Hansens Disease (Leprosy) Program. Available at <a href=\"http://www.hrsa.gov/hansensdisease/\" target=\"_blank\">http://www.hrsa.gov/hansensdisease/</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kabra NS, Nanavati RN, and Srinivasan G, &quot;Neonatal Methemoglobinemia Due to Transplacental Transfer of Dapsone,&quot; <i>Indian Pediatr</i>, 1998, 35(6):553-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/10216653 /pubmed\" target=\"_blank\" id=\"10216653 \">10216653 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kenani N, Mebazaa A, Denguezli M, et al. Childhood linear IgA bullous dermatosis in Tunisia. <i>Pediatric Dermatology </i>. 2009;26(1):28-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19250401/pubmed\" target=\"_blank\" id=\"19250401\">19250401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kishida Y, Kameyama J, Nei M, Hashimoto T, Baba K. Linear IgA bullous dermatosis of neonatal onset: case report and review of the literature. <i>Acta Paediatr</i>. 2004;93:850-854.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meeker ND, Goldsby R, Terrill KR, Delaney KS, Slayton WB. Dapsone therapy for children with immune thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2003;25(2):173-175.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/12571474/pubmed\" target=\"_blank\" id=\"12571474\">12571474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirochnick M, Michaels M, Clarke D, et al, &quot;Pharmacokinetics of Dapsone in Children,&quot; <i>J Pediatr</i>, 1993, 122(5 Pt 1):806-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8496767/pubmed\" target=\"_blank\" id=\"8496767\">8496767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanders SW, Zone JJ, Foltz RL, et al, &quot;Hemolytic Anemia Induced by Dapsone Transmitted Through Breast Milk,&quot; <i>Ann Intern Med</i>, 1982, 96(4):465-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/7065565/pubmed\" target=\"_blank\" id=\"7065565\">7065565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stavola JJ and Noel GJ, &quot;Efficacy and Safety of Dapsone Prophylaxis Against <i>Pneumocystis carinii</i> Pneumonia in Human Immunodeficiency Virus-Infected Children,&quot; <i>Pediatr Infect Dis J</i>, 1993, 12(8):644-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/8414776/pubmed\" target=\"_blank\" id=\"8414776\">8414776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thappa DM, Jeevankumar B. Chronic bullous dermatosis of childhood. <i>Postgrad Med J</i>. 2003;79(934):437.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/12954953/pubmed\" target=\"_blank\" id=\"12954953\">12954953</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thornton YS and Bowe ET, &quot;Neonatal Hyperbilirubinemia After Treatment of Maternal Leprosy,&quot; <i>South Med J</i>, 1989, 82(5):668. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/2717998 /pubmed\" target=\"_blank\" id=\"2717998 \">2717998 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15:1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. WHO model formulary for children. 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuidema J, Hilbers-Modderman ES, and Merkus FW, &ldquo;Clinical Pharmacokinetics of Dapsone,&rdquo; <i>Clin Pharmacokinet</i>, 1986, 11(4):299-315.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dapsone-systemic-pediatric-drug-information/abstract-text/3530584/pubmed\" target=\"_blank\" id=\"3530584\">3530584</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15963 Version 154.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10483704\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F24552552\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10483725\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8015379\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9490508\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10483764\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8015308\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10483705\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8015264\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8015299\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8015294\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8015295\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8015301\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8015302\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8015289\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8015290\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10483765\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8015309\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8015311\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F8015382\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322077\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390227\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15963|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dapsone-systemic-drug-information\" class=\"drug drug_general\">Dapsone (systemic): Drug information</a></li><li><a href=\"topic.htm?path=dapsone-systemic-patient-drug-information\" class=\"drug drug_patient\">Dapsone (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}